Loading patent…
AssigneeBayer Schering Pharma Aktiengesellschaft
InventorsStefan Golz, Ulf Brüggemeier, Bernhard Weingärtner, Andreas Geerts
Estimating the term…
The present invention is directed to a polynucleotide sequence of a novel acylglycerol acyltransferase-like protein MGAT-X1. The invention also provides the human MGAT-X1 associated with the dermatological diseases, urological diseases, muscle-skeleton disorders, hematological diseases, cancer, reproduction disorders, neurological diseases, metabolic diseases, cardiovascular diseases or gastroenterological diseases. The invention also provides assays for the identification of compounds useful for the modulation of dermatological diseases, urological diseases, muscle-skeleton disorders, hematological diseases, cancer, reproduction disorders, neurological diseases, metabolic diseases, cardiovascular diseases or gastroenterological diseases for treating of such diseases associated with expression of the MGAT-X1. The invention also features compounds which bind to and/or activate or inhibit the activity of MGAT-X1 as well as pharmaceutical compositions comprising such compounds.
A purified polypeptide comprising the amino acid sequence SEQ ID NO:2.
A purified polypeptide comprising an amino acid sequence which is at least 80% identical to the amino acid sequence SEQ ID NO:2.
A fusion polypeptide comprising two polypeptide segments fused together by means of a peptide bond, wherein a first polypeptide segment comprises at least 54 contiguous amino acids of SEQ ID NO:2.
A composition comprising:
Dependencies are inferred from the claim text.